CER-T Cell Platform
Hematologic Malignancies
Key Facts
About CERo Therapeutics
CERo Therapeutics is developing next-generation cell therapies designed to overcome limitations of current immunotherapies by creating multifunctional T cells. Its proprietary CER platform engineers T cells to recognize 'Eat Me' signals on tumors, enabling them to engulf cancer cells, kill them directly, and present tumor antigens to stimulate a broader, secondary immune response. This integrated approach aims to enhance curative potential and safety, positioning CERo in the competitive but high-potential field of advanced cell therapies for oncology.
View full company profileAbout CERo Therapeutics
CERo Therapeutics is developing next-generation cell therapies designed to overcome limitations of current immunotherapies by creating multifunctional T cells. Its proprietary CER platform engineers T cells to recognize 'Eat Me' signals on tumors, enabling them to engulf cancer cells, kill them directly, and present tumor antigens to stimulate a broader, secondary immune response. This integrated approach aims to enhance curative potential and safety, positioning CERo in the competitive but high-potential field of advanced cell therapies for oncology.
View full company profileTherapeutic Areas
Other Hematologic Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1905 | Jiangsu Hengrui Medicine | Phase 1 |
| Rituximab biosimilar (IBI301) | Innovent Biologics | Approved |
| Alemtuzumab Biosimilar | CSPC Pharmaceutical Group Limited | Phase 3 |
| Lead CAR-T Program | Arcellx | Phase 1 |
| KT-333 | Kymera Therapeutics | Phase 1 |
| Undisclosed CAR-T programs | Beam Therapeutics | Discovery/Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| Trichostatin A (TSA) | Vanda Pharmaceuticals | Oncology Program |
| Cord Blood HSC Unit | Global Cord Blood | Approved/Commercial |
| TSC-102-A01 | TScan Therapeutics | Preclinical |
| TSC-102-A03 | TScan Therapeutics | Preclinical |
| LBL-007 | LakeShore Biopharma | Phase 1 |